Eichenfield LF, Siegfried E, Kwong P, et al. - Researchers sought to report pooled safety and efficacy analyses of VP-102, which is a shelf-stable drug–device combination product that contains topical cantharidin (0.7% weight/volume [w/v]), in the treatment of molluscum compared with vehicle. In total, 310 and 218 participants received VP-102 and vehicle, respectively. As per pooled analyses, there was a significantly higher percentage of participants with complete molluscum lesion clearance and larger decreases in lesion counts with VP-102 vs vehicle. Because of the pharmacodynamic properties of cantharidin, adverse events (AEs) were anticipated. Application site blistering, pruritus, pain, and erythema were the most common AEs in the VP-102 group, which were generally mild to moderate in severity.